SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 11, 2019-- Tricida, Inc., (Nasdaq: TCDA) a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 7, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and the year ended December 31, 2018 financial results at 7:00 am Eastern Time on Thursday, March 28, 2019 .

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 27, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 8:20 am PT / 11:20 am ET . Geoff Parker , Tricida’s Chief Financial Officer,

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 17, 2019-- Tricida, Inc. (Nasdaq: TCDA), today announced the hiring of Susannah Cantrell , Ph.D., as Chief Commercial Officer and Senior Vice President. Dr. Cantrell will lead Tricida’s commercial planning and operations functions.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 2, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 37 th Annual J. P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 11:30 am PT / 2:30 pm ET . Gerrit Klaerner , Ph.D., Tricida’s chief executive